LONDON, March 20, 2014 /PRNewswire/ --
The US markets saw a negative sentiment on Wednesday, March 19, 2014, with the NASDAQ
Composite closing at 4,307.60, down 0.59%, the Dow Jones Industrial
Average ending the session at 16,222.17, down 0.70% and the S&P
500 edging 0.61% lower to finish the trading session at 1,860.77.
The losses were broad based as all the ten sectors ended the
session in negative. A number of stocks saw large movements,
including First Solar Inc. (NASDAQ: FSLR), Oncothyreon Inc.
(NASDAQ: ONTY), Unilife Corp. (NASDAQ: UNIS), and Synthetic
Biologics Inc. (AMEX: SYN). Free technical research on FSLR, ONTY,
UNIS, and SYN can be downloaded upon signing up at:
http://www.investor-edge.com/348-register
Shares in First Solar Inc. edged 20.57% higher, finishing
Wednesday's session at $69.40,
hitting a new 52-week high of $70.99.
The stock fluctuated between $56.96 and
$70.99 during the session with a trading volume of 30.82
million shares as compared to a three months average volume of 4.00
million shares. Shares in First Solar Inc. have gained 28.45% in
the previous three trading sessions and 22.27% in the last three
months. The company's shares are traded at a PE ratio of 16.65 and
have gone up 27.01% on YTD basis. The S&P 500 Information
Technology Sector Index mapped a loss of 0.52% during the trading
session and charted up 1.14% in the last one month. Furthermore,
the stock is trading at the RSI of 57.82 and above its 50-day and
200-day moving averages of $53.03 and
$49.60, respectively. Sign up today
to read free research on FSLR at:
http://www.investor-edge.com/348-FSLR-20Mar2014.pdf
Oncothyreon Inc.'s stock closed Wednesday's session at $3.60, which is 6.19% higher than the previous
day's closing price of $3.39. A total
of 1.94 million shares were traded as compared to a three months
average volume of 0.94 million shares. The stock oscillated between
$3.19 and $3.62 during the trading
session. Oncothyreon Inc.'s shares have surged 24.14% in the last
one month, 103.39% in the previous three months and 104.55% on YTD
basis. The S&P 500 Health Care Sector Index mapped a loss of
0.37% during the trading session and charted up 8.42% in the
previous three months. Moreover, the stock is trading at the RSI of
56.49 and above its 50-day and 200-day moving averages of
$2.69 and $2.03, respectively. Sign up today to read free
research on ONTY at:
http://www.investor-edge.com/348-ONTY-20Mar2014.pdf
On Wednesday, shares in Unilife Corp. ended the session at
$5.74, up 12.55%, hitting a new
52-week high of $5.80. A total of
5.36 million shares were traded as compared to a three months
average volume of 1.13 million shares. During the session, the
stock traded between $5.05 and $5.80.
Unilife Corp.'s shares have advanced 36.67% in the last one month,
38.65% in the previous three months and 30.45% on YTD basis. The
S&P 500 Health Care Sector Index mapped a loss of 0.37% during
the trading session and charted up 1.70% in the last one month.
Further, the stock is trading at the RSI of 66.37 and above its
50-day and 200-day moving averages of $4.47 and $3.66,
respectively. Sign up today to read free research on UNIS at:
http://www.investor-edge.com/348-UNIS-20Mar2014.pdf
Synthetic Biologics Inc.'s stock finished Wednesday's session at
$3.45, recording a 9.52% gain, after
hitting a new 52-week high of $3.64.
A total of 5.35 million shares were traded which is above the three
months average volume of 1.15 million shares. The stock vacillated
between $3.25 and $3.64 during the
session. Synthetic Biologics Inc.'s shares have rallied 26.84% in
the last one month, 210.81% in the previous three months and
125.49% on YTD basis. The S&P 500 Health Care Sector Index
declined 0.37% during the trading session, while the same has
gained 1.72% in the previous three trading sessions. Additionally,
the stock is trading at the RSI of 70.13 and above its 50-day and
200-day moving averages of $2.28 and
$1.72, respectively. Sign up today to
read free research on SYN at:
http://www.investor-edge.com/348-SYN-20Mar2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to research [at]
http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Nidhi Vatsal, CFA, has only reviewed the information provided by
Investor-edge in this article or report according to the Procedures
outlined by Investor-edge. Investor-edge is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Investor-Edge